Cargando…

Are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire?

BACKGROUND/OBJECTIVE: The Self Assessment of Treatment (SAT) questionnaire was developed to reflect key patient reported outcomes of Neuropathic Pain (NP) treatments. This study aimed to understand how patients perceived the relevance and ease of understanding of the questions in the SAT and to reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiklund, Ingela, Holmstrom, Stefan, Stoker, Malcolm, Wyrwich, Kathleen W, Devine, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598534/
https://www.ncbi.nlm.nih.gov/pubmed/23332037
http://dx.doi.org/10.1186/1477-7525-11-8
_version_ 1782262780964896768
author Wiklund, Ingela
Holmstrom, Stefan
Stoker, Malcolm
Wyrwich, Kathleen W
Devine, Mary
author_facet Wiklund, Ingela
Holmstrom, Stefan
Stoker, Malcolm
Wyrwich, Kathleen W
Devine, Mary
author_sort Wiklund, Ingela
collection PubMed
description BACKGROUND/OBJECTIVE: The Self Assessment of Treatment (SAT) questionnaire was developed to reflect key patient reported outcomes of Neuropathic Pain (NP) treatments. This study aimed to understand how patients perceived the relevance and ease of understanding of the questions in the SAT and to recommend modifications based on patient and clinician interviews. METHODS: Semi-structured interviews were conducted with clinicians and NP patients to provide information regarding treatment attributes and the impact of pain. Patients were debriefed on the SAT, a 5-item scale evaluating pain, activity level, quality of life (QoL) and satisfaction with treatment (recommend treatment and undergo treatment again). The SAT has a recall period reflecting back to the start of treatment. The qualitative analysis software ATLAS.ti 5.0 was used to analyze patient transcripts. Changes to the SAT were integrated into the questionnaire for a second round of debriefing interviews. RESULTS: Three NP clinicians and 44 patients (20 painful diabetic neuropathy, 16 HIV-associated neuropathy and 8 post herpetic neuralgia) with a mean age of 60.3 (12.3) years and an even gender distribution were interviewed. Patient treatment experience included anticonvulsants (73%), antidepressants (34%), opioids (25%), and topical medications (41%). Pain descriptors and treatment attributes were similar across the three NP groups. Pain relief was judged the most important treatment attribute, followed by ability to undertake activities. Sleep improvement was another important attribute. Activity limitations and QOL were perceived as too broad and non-specific, and were split into 3 concepts each (activity limitations was split into self care, daily and physical activities and QOL was split into sleep, emotions, and social function). A 7-day recall period was introduced. The item stem and response options were made consistent, and a baseline and follow-up questionnaires were developed (except for the satisfaction items) to enable monitoring onset of treatment benefit and change over time. CONCLUSIONS: The content validity of the revised SAT was improved by the qualitative research, and NP treatment benefits are reflected in a more consistent fashion by the changes. Baseline and follow-up versions make it possible to perform assessments of change over time.
format Online
Article
Text
id pubmed-3598534
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35985342013-03-16 Are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire? Wiklund, Ingela Holmstrom, Stefan Stoker, Malcolm Wyrwich, Kathleen W Devine, Mary Health Qual Life Outcomes Research BACKGROUND/OBJECTIVE: The Self Assessment of Treatment (SAT) questionnaire was developed to reflect key patient reported outcomes of Neuropathic Pain (NP) treatments. This study aimed to understand how patients perceived the relevance and ease of understanding of the questions in the SAT and to recommend modifications based on patient and clinician interviews. METHODS: Semi-structured interviews were conducted with clinicians and NP patients to provide information regarding treatment attributes and the impact of pain. Patients were debriefed on the SAT, a 5-item scale evaluating pain, activity level, quality of life (QoL) and satisfaction with treatment (recommend treatment and undergo treatment again). The SAT has a recall period reflecting back to the start of treatment. The qualitative analysis software ATLAS.ti 5.0 was used to analyze patient transcripts. Changes to the SAT were integrated into the questionnaire for a second round of debriefing interviews. RESULTS: Three NP clinicians and 44 patients (20 painful diabetic neuropathy, 16 HIV-associated neuropathy and 8 post herpetic neuralgia) with a mean age of 60.3 (12.3) years and an even gender distribution were interviewed. Patient treatment experience included anticonvulsants (73%), antidepressants (34%), opioids (25%), and topical medications (41%). Pain descriptors and treatment attributes were similar across the three NP groups. Pain relief was judged the most important treatment attribute, followed by ability to undertake activities. Sleep improvement was another important attribute. Activity limitations and QOL were perceived as too broad and non-specific, and were split into 3 concepts each (activity limitations was split into self care, daily and physical activities and QOL was split into sleep, emotions, and social function). A 7-day recall period was introduced. The item stem and response options were made consistent, and a baseline and follow-up questionnaires were developed (except for the satisfaction items) to enable monitoring onset of treatment benefit and change over time. CONCLUSIONS: The content validity of the revised SAT was improved by the qualitative research, and NP treatment benefits are reflected in a more consistent fashion by the changes. Baseline and follow-up versions make it possible to perform assessments of change over time. BioMed Central 2013-01-18 /pmc/articles/PMC3598534/ /pubmed/23332037 http://dx.doi.org/10.1186/1477-7525-11-8 Text en Copyright ©2013 Wiklund et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Wiklund, Ingela
Holmstrom, Stefan
Stoker, Malcolm
Wyrwich, Kathleen W
Devine, Mary
Are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire?
title Are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire?
title_full Are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire?
title_fullStr Are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire?
title_full_unstemmed Are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire?
title_short Are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire?
title_sort are treatment benefits in neuropathic pain reflected in the self assessment of treatment questionnaire?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598534/
https://www.ncbi.nlm.nih.gov/pubmed/23332037
http://dx.doi.org/10.1186/1477-7525-11-8
work_keys_str_mv AT wiklundingela aretreatmentbenefitsinneuropathicpainreflectedintheselfassessmentoftreatmentquestionnaire
AT holmstromstefan aretreatmentbenefitsinneuropathicpainreflectedintheselfassessmentoftreatmentquestionnaire
AT stokermalcolm aretreatmentbenefitsinneuropathicpainreflectedintheselfassessmentoftreatmentquestionnaire
AT wyrwichkathleenw aretreatmentbenefitsinneuropathicpainreflectedintheselfassessmentoftreatmentquestionnaire
AT devinemary aretreatmentbenefitsinneuropathicpainreflectedintheselfassessmentoftreatmentquestionnaire